https://www.selleckchem.com/pr....oducts/alofanib-rpt8
ersus 1.8 mo, HR= 0.57 [95% CI 0.38-0.84], p= 0.005), and a significantly shorter mOS (15.5 versus 8.2 mo, HR= 0.56 [95% CI 0.36-0.86], p= 0.008). The deleterious effect on immunotherapy outcomes in KRAS-mutant NSCLC was most pronounced in the SMARCA4-mutant subset (N= 17), with a lower ORR (22% versus 0%, p= 0.03), a significantly shorter mPFS (4.1 versus 1.4 mo, HR= 0.25 [95% CI 0.14-0.42], p 0.001), and a significantly shorter mOS (15.1 versus 3.0 mo, HR= 0.29 [95% CI 0.17-0.50], p 0.001) compared with SMARCA4-wt KR
Like
Comment
Share
